130 related articles for article (PubMed ID: 38710467)
1. Granulocyte and monocyte adsorptive apheresis (GMA) in patients with inflammatory bowel disease: A useful therapeutic tool not just in ulcerative colitis but also in Crohn's disease.
Fernández-Pérez FJ; Fernández-Moreno N; Soria-López E; Rodriguez-González FJ; Fernández-Galeote FJ; Lifante-Oliva A; Ruíz-Hernández C; Escalante-Quijaite E; Rivas-Ruiz F
Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38710467
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with the outcomes in ulcerative colitis patients undergoing granulocyte and monocyte adsorptive apheresis as remission induction therapy: A multicenter cohort study.
Ishiguro Y; Ohmori T; Umemura K; Iizuka M
Ther Apher Dial; 2021 Aug; 25(4):502-512. PubMed ID: 33029920
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of granulocyte and monocyte adsorption apheresis in paediatric inflammatory bowel disease: a prospective pilot study.
Martín de Carpi J; Vilar P; Prieto G; García Novo MD; Ribes C; Varea V
J Pediatr Gastroenterol Nutr; 2008 Apr; 46(4):386-91. PubMed ID: 18367949
[TBL] [Abstract][Full Text] [Related]
4. Targeting neutrophils in inflammatory bowel disease: revisiting the role of adsorptive granulocyte and monocyte apheresis.
Bamias G; Zampeli E; Domènech E
Expert Rev Gastroenterol Hepatol; 2022 Aug; 16(8):721-735. PubMed ID: 35833363
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte-monocyte adsorptive apheresis in pediatric inflammatory bowel disease: results, practical issues, safety, and future perspectives.
Ruuska T; Wewer V; Lindgren F; Malmborg P; Lindquist M; Marthinsen L; Browaldh L; Casswall T; Kalliomäki M; Grönlund J
Inflamm Bowel Dis; 2009 Jul; 15(7):1049-54. PubMed ID: 19137602
[TBL] [Abstract][Full Text] [Related]
6. [Granulocytapheresis in inflammatory bowel disease. Efficacy of an induction plus maintenance sessions protocol at 32 weeks].
Fernández Pérez FJ; Rodríguez F; de Sola C; Fernández Moreno N; Vera F; Rivera R; Sánchez Cantos A
Rev Esp Enferm Dig; 2007 Nov; 99(11):628-35. PubMed ID: 18271660
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study.
Yokoyama Y; Watanabe K; Ito H; Nishishita M; Sawada K; Okuyama Y; Okazaki K; Fujii H; Nakase H; Masuda T; Fukunaga K; Andoh A; Nakamura S
Cytotherapy; 2015 May; 17(5):680-8. PubMed ID: 25804800
[TBL] [Abstract][Full Text] [Related]
8. Adsorptive Depletion of Myeloid Lineage Leucocytes as Remission Induction Therapy in Patients with Ulcerative Colitis after Failure of First-Line Medications: Results from a Three-Year Real World, Clinical Practice.
Iida T; Ikeya K; Kato M; Abe J; Yamamoto M; Watanabe F; Sugimoto K; Hanai H
Digestion; 2017; 96(2):119-126. PubMed ID: 28796990
[TBL] [Abstract][Full Text] [Related]
9. Adsorptive granulocyte/monocyte apheresis for the maintenance of remission in patients with ulcerative colitis: a prospective randomized, double blind, sham-controlled clinical trial.
Fukunaga K; Yokoyama Y; Kamokozuru K; Nagase K; Nakamura S; Miwa H; Matsumoto T
Gut Liver; 2012 Oct; 6(4):427-33. PubMed ID: 23170145
[TBL] [Abstract][Full Text] [Related]
10. Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications.
Tanaka T; Sugiyama S; Goishi H; Kajihara T; Akagi M; Miura T
BMC Gastroenterol; 2013 Aug; 13():130. PubMed ID: 23961883
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis.
Dignass A; Akbar A; Baumgart DC; Bommelaer G; Bouguen G; Cadiot G; Gillessen A; Grimaud JC; Hart A; Hoque S; Makins R; Michiels C; Moreau J; Premchand P; Ramlow W; Schanz S; Subramanian S; von Tirpitz C; Bonaz B
Scand J Gastroenterol; 2018 Apr; 53(4):442-448. PubMed ID: 29513111
[TBL] [Abstract][Full Text] [Related]
12. Concomitant pharmacologic medications influence the clinical outcomes of granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis: A multicenter retrospective cohort study.
Ueno N; Sugiyama Y; Kobayashi Y; Murakami Y; Iwama T; Sasaki T; Kunogi T; Sakatani A; Takahashi K; Tanaka K; Serikawa S; Ando K; Kashima S; Muto M; Inaba Y; Moriichi K; Tanabe H; Okumura T; Fujiya M
J Clin Apher; 2023 Aug; 38(4):406-421. PubMed ID: 36636880
[TBL] [Abstract][Full Text] [Related]
13. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P
Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573
[TBL] [Abstract][Full Text] [Related]
14. The Italian Registry of Therapeutic Apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study.
Passalacqua S; Ferraro PM; Bresci G; D'Ovidio V; Astegiano M; Principi M; Testa R; D'Incà R; Valpiani D; Armuzzi A; Sablich R; Cavallaro F; Costa F; Di Leo V; Colombo E; Santini A; Aratari A; Lecis P; Saladino V; Riegler G; Marco M; Calella F; Ricci C; Guidi ML; Repaci G; Silla M
J Clin Apher; 2011 Dec; 26(6):332-7. PubMed ID: 22072543
[TBL] [Abstract][Full Text] [Related]
15. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety.
Christensen B; Colman RJ; Micic D; Gibson PR; Goeppinger SR; Yarur A; Weber CR; Cohen RD; Rubin DT
Inflamm Bowel Dis; 2018 Mar; 24(4):849-860. PubMed ID: 29562271
[TBL] [Abstract][Full Text] [Related]
16. Intensive Frequent Granulocyte Adsorptive Apheresis Therapy for Acute Fulminant Ulcerative Colitis: Two Consecutive Case Reports.
Furuto Y; Sawada R; Namikawa A; Matsuhashi N; Shibuya Y
Cureus; 2023 Aug; 15(8):e43599. PubMed ID: 37719478
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study.
Motoya S; Tanaka H; Shibuya T; Osada T; Yamamoto T; Hongo H; Mizuno C; Saito D; Aoyama N; Kobayashi T; Ito H; Tanida S; Nojima M; Kokuma S; Hosoi E
BMC Gastroenterol; 2019 Nov; 19(1):196. PubMed ID: 31752695
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease.
Lindberg A; Eberhardson M; Karlsson M; Karlén P
BMC Gastroenterol; 2010 Jul; 10():73. PubMed ID: 20604939
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory bowel disease patients experiencing a loss of response to infliximab regain long-term response after undergoing granulocyte/monocyte apheresis: A case series.
Yokoyama Y; Kamikozuru K; Watanabe K; Nakamura S
Cytokine; 2018 Mar; 103():25-28. PubMed ID: 29291447
[TBL] [Abstract][Full Text] [Related]
20. Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn's Disease.
Ozeki K; Tanida S; Mizoshita T; Tsukamoto H; Ebi M; Mori Y; Kataoka H; Kamiya T; Joh T
Case Rep Gastroenterol; 2012 Sep; 6(3):765-71. PubMed ID: 23341799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
